James Krellenstein is a co-founder of The PrEP4All Collaboration and the #BreakThePatent movement. For more information, please visit www.breakthepatent.org.
Latest by James Krellenstein
In order to adequately address the HIV epidemic in the United States, two advocates argue that the high cost of antiretroviral drugs must be addressed.
On Nov. 20, 2018, the U.S. Preventive Services Task Force released a draft recommendation that could transform HIV-1 pre-exposure prophylaxis (PrEP) scale-up in the United States.
"A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified -- cost shouldn't be one of them," write James Krellenstein and Jeremiah Johnson.